TMF Attenuates Cognitive Impairment and Neuroinflammation by Inhibiting the MAPK/NF-κB Pathway in Alzheimer’s Disease: A Multi-Omics Analysis

Yonglin Liu, Xi Xu, Xiao-Ming Wu, Guodong Yang, Jiaxin Luo, Xin‐Li Liang, Jie Chen, Yiguang LiMarine 2025 · DOI

TL;DR

This study investigates the potential of 3′,4′,5,7-tetramethoxyflavone (TMF), a natural flavonoid, as a treatment for Alzheimer's Disease (AD). TMF effectively improved cognitive function and reduced key AD pathologies like amyloid-beta plaques and neuroinflammation in mouse models by inhibiting the MAPK/NF-κB signaling pathway.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a devastating neurodegenerative condition with a growing prevalence and a significant unmet need for effective treatments. While current therapies offer symptomatic relief, they don't halt disease progression. Neuroinflammation is a critical driver of AD pathology, contributing to cognitive decline and neuronal damage. Identifying novel therapeutic agents that can effectively target neuroinflammation and ameliorate AD symptoms is therefore a major research focus. This paper addresses the need to understand the efficacy and underlying mechanisms of TMF, a promising natural compound, in combating AD.

Methods

The researchers employed a multi-pronged approach combining in vivo and in vitro experiments with multi-omics analyses.

  • In Vivo Studies: They used the APP/PS1 transgenic mouse model, which recapitulates key AD pathologies, to assess TMF's effects on cognitive function (Morris Water Maze, Open-Field Test) and AD hallmarks (amyloid-beta and tau pathology via immunohistochemistry and Western blot). Neuroinflammation was evaluated by measuring cytokine levels (TNF-α, IL-1β, IL-6) and glial activation markers (Iba1, GFAP).
  • In Vitro Studies: LPS-stimulated BV2 microglia cells were used to model neuroinflammation. TMF's effects on nitric oxide (NO) production, inflammatory gene expression (iNOS, COX-2, TNF-α, IL-6), and the activation of key signaling pathways (MAPK/NF-κB) were investigated.
  • Multi-Omics Analysis:
    • Transcriptomics (RNA-seq): Performed on hippocampal tissue to identify differentially expressed genes (DEGs) and pathways affected by TMF treatment. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were used to understand the functional implications of these changes. Gene Set Enrichment Analysis (GSEA) specifically explored pathway activation.
  • Metabolomics: Untargeted metabolomics was used to analyze plasma metabolite profiles and identify how TMF impacts metabolic pathways.
  • Molecular Mechanistic Studies: Western blotting was used to assess the phosphorylation levels of key proteins in the MAPK/NF-κB pathway (ERK, JNK, P38, NF-κB p65) in both mouse brains and BV2 cells. Immunofluorescence was used to visualize NF-κB p65 localization in BV2 cells.

Datasets

  • APP/PS1 Mouse Model: A well-established mouse model for Alzheimer's disease research.
  • BV2 Microglia Cell Line: A standard cell line used for studying microglial activation and neuroinflammation.
  • Transcriptomic Data: RNA-seq data from hippocampal tissue of APP/PS1 mice treated with TMF.
  • Metabolomic Data: Plasma metabolite profiles from APP/PS1 mice treated with TMF.

No new benchmarks were introduced; standard models and analytical techniques were utilized.

Key Insights and Ideas

  • TMF as a Multi-Target Agent: The study highlights TMF's ability to address multiple facets of AD pathology, including cognitive decline, amyloid and tau burden, and crucially, neuroinflammation. This suggests TMF could be a more comprehensive therapeutic than single-target drugs.
  • MAPK/NF-κB Pathway as a Central Target: The consistent finding across transcriptomics, Western blotting, and in vitro studies that TMF inhibits the MAPK/NF-κB pathway is a major insight. This pathway is a critical regulator of inflammation, and its modulation by TMF provides a clear mechanistic link to its observed therapeutic effects.
  • Synergy of Multi-Omics: The integration of transcriptomics and metabolomics provided a holistic view of TMF's impact, revealing not only gene expression changes but also alterations in metabolic pathways that are linked to inflammation and AD. This approach strengthens the mechanistic understanding.
  • Natural Compounds as Viable AD Therapeutics: The study reinforces the potential of natural products, like flavonoids, as sources for novel AD therapies, building upon previous research on luteolin.

Key Results

  • Cognitive Improvement: A dose of 40 mg/kg TMF significantly improved memory and reduced anxiety-like behaviors in APP/PS1 mice. A lower dose (10 mg/kg) showed no significant effect, suggesting a dose-dependent response.
  • Reduced AD Pathology: TMF treatment (40 mg/kg) reduced amyloid-beta (Aβ) plaque deposition and p-tau levels in the brains of APP/PS1 mice.
  • Suppressed Neuroinflammation: TMF significantly decreased pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6) and reduced the activation of microglia (Iba1) and astrocytes (GFAP) in APP/PS1 mice.
  • MAPK/NF-κB Inhibition: TMF treatment led to decreased phosphorylation of ERK, JNK, P38 MAPK, and NF-κB p65 in both mouse brains and LPS-stimulated BV2 cells. This directly demonstrates TMF's mechanism of action.
  • Metabolic Modulation: Metabolomics revealed that TMF altered plasma metabolite profiles, with significant enrichment in pathways like arginine and proline metabolism, which are linked to inflammation.

Limitations and Future Work

  • Optimal Dosage: While 40 mg/kg TMF was effective, the study suggests that 20 mg/kg might be the minimum effective dose, warranting further investigation to pinpoint the optimal therapeutic window.
  • Broader Metabolic Impact: The study identified metabolic alterations but suggests further research is needed to fully explore the broader metabolic impact of TMF in AD models.
  • Long-Term Efficacy: The current study focused on a specific time point; long-term efficacy and safety studies would be beneficial.
  • Clinical Translation: While promising, these findings are from preclinical models and require further validation in clinical trials to assess TMF's therapeutic potential in humans.

The authors propose future research to delve deeper into the molecular mechanisms and broader metabolic effects of TMF in AD.

Summary updated

Abstract

The rising prevalence of Alzheimer's disease (AD) underscores the urgent need for novel therapeutic agents derived from natural sources. Among flavonoids, 3',4',5,7-tetramethoxyflavone (TMF), a structural analog of luteolin, has gained attention for its favorable pharmacokinetics and potential neuroprotective properties. Despite the significant neuroprotective effects and favorable pharmacokinetics of TMF, its efficacy and mechanism of action in AD remain unclear. This study explored TMF's pharmacological effects in AD models, highlighting its ability to improve memory and cognitive deficits in APP/PS1 mice. TMF reduced Aβ plaques, NFTs formation, and glial activation while suppressing neuroinflammation through the MAPK/NF-κB pathway. Further analysis in LPS-induced BV2 cells revealed TMF's ability to reduce microglial activation. These findings highlight the anti-neuroinflammatory activity of TMF, suggesting its potential as a treatment for AD.
BibTeX
@inproceedings{liu2025tmf,
  author = {Yonglin Liu and Xi Xu and Xiao-Ming Wu and Guodong Yang and Jiaxin Luo and Xin‐Li Liang and Jie Chen and Yiguang Li},
  title = {{TMF Attenuates Cognitive Impairment and Neuroinflammation by Inhibiting the MAPK/NF-κB Pathway in Alzheimer’s Disease: A Multi-Omics Analysis}},
  booktitle = {Marine},
  year = {2025},
  doi = {10.3390/md23020074},
}
Figure